BioSpace News Archive

Neuronascent Inc., a clinical-stage, neuron generating, biopharmaceutical company, is pleased to announce the addition of industry leader Emer Leahy, Ph.D., MBA, to its Board of Directors.

Kineta, Inc. announced the first patient has been dosed in a Phase 1/2 clinical study evaluating KVA12123 alone and in combination with the immune checkpoint inhibitor pembrolizumab in patients with advanced solid tumors.

Function Oncology, a company transforming the future of targeted cancer treatment with a CRISPR-powered precision medicine platform, announced an upcoming presentation at the American Association for Cancer Research 2023 Annual Meeting.

Oncolytics Biotech® Inc. is pleased to announce its notice of the annual general meeting of shareholders and management information circular are now available on the Company’s website at: www.oncolyticsbiotech.com as well as under Oncolytics’ profile on SEDAR.

Arbor Biotechnologies®, a biotechnology company discovering and developing the next generation of genetic editing medicines, announced the appointment of Daniel Ory, M.D., as Chief Medical Officer.

ONL Therapeutics, Inc. today announced that the first patient has been dosed in its Phase 2 clinical trial of ONL1204 Ophthalmic Solution in patients with macula-off rhegmatogenous retinal detachment (RRD).

Verrica Pharmaceuticals Inc. (“Verrica” or, the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that the first patient has been dosed in Part 2 of a Phase 2 study evaluating the Company’s potentially first-in-class oncolytic peptide, VP-315, for the treatment of basal cell carcinoma.

GreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to deliver on the full potential of RNA to address some of the world’s toughest problems in human health and agriculture, today released its inaugural Sustainability Report.

Clearside Biomedical, Inc. announced today that George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer, will participate in a Fireside Chat at the 22nd Annual Needham Virtual Healthcare Conference on Wednesday, April 19, 2023, at 1:30 p.m. ET.

Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, May 3, 2023 , at 8:00 a.m. CDT to review third quarter 2023 financial results.